{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:46:40Z","timestamp":1792806400178,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on patients\u2019 health-related quality of life (HRQL). Acute and preventive treatments may lift the burden of the disease, but they often have unwanted side effects and limited effectiveness. The objective of this study was to understand the interictal burden of migraines, from the patient perspective, and to explore patient experience with migraine treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants (n=35) with a self-reported diagnosis of migraine were recruited in the US, UK and Canada, including a subgroup of patients who had taken calcitonin gene-related peptide monoclonal antibody (CGRP mAb) treatment for at least three months. Participants completed a background questionnaire, followed by a semi-structured interview via telephone or video call. The interviews explored patients\u2019 migraine symptoms, perception of interictal burden and treatment experience. The interview transcripts were analysed using thematic analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most reported migraine symptom was migraine pain, followed by aura, sensory sensitivity and nausea. Most participants reported interictal impact on HRQL, lifestyle changes they made to avoid triggers or in anticipation of an attack, impacts on work, career, daily activities and relationships. Emotional impacts were reported by all participants, including anger, depression, anxiety and hopelessness. Many participants who took preventive treatments reported improvements in HRQL and functioning but still experienced breakthrough attacks. Among patients who took CGRP mAbs, participants noted varying consistency of treatment effectiveness between treatment administrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study detailed the additional HRQL impact of migraine in-between migraine attacks and described the unmet need for effective treatment options to prevent and mitigate migraine attacks.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-022-01429-5","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T07:14:38Z","timestamp":1654672478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Real-World experience of interictal burden and treatment in migraine: a qualitative interview study"],"prefix":"10.1186","volume":"23","author":[{"given":"Siu Hing","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Gallop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena T.","family":"Hubig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"1429_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A, Krymchantowski AV, Lebedava ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"1429_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 97:553\u2013622","journal-title":"Physiol Rev"},{"key":"1429_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBD 2016\u00a0Headache Collaborators","year":"2018","unstructured":"GBD 2016\u00a0Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology 17:954\u2013976","journal-title":"Lancet Neurology"},{"key":"1429_CR4","doi-asserted-by":"crossref","unstructured":"Shrewsbury SB, Ailani J, Ray S, Aurora SK, Hoekman J (2020) Impact and burden of episodic, acute migraine: A patient experience study. Headache. Conference: 62nd Annual Scientific Meeting American Headache Society 60 (Supplement 1):71.","DOI":"10.1111\/head.13854"},{"key":"1429_CR5","first-page":"644","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, Wilcox TK, Kawata AK, Lipton RB (2013) Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II). Headache: The Journal of Head and Face. Pain 53:644\u2013655","journal-title":"Pain"},{"key":"1429_CR6","unstructured":"Lundbeck Seattle (2020) Vyepti (eptinezumab-jjmr) [package insert]."},{"key":"1429_CR7","unstructured":"Amgen Inc. & Novartis AG (2018) Aimovig (erenumab-aooe) [package insert]."},{"key":"1429_CR8","unstructured":"Teva Pharmaceuticals USA Inc. (2018) AJOVY (fremanezumab) [package insert]."},{"key":"1429_CR9","unstructured":"Eli Lilly and Company (2019) Emgality (galcanezumab-gnlm) [package insert]."},{"key":"1429_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","volume":"21","author":"R Ornello","year":"2020","unstructured":"Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32","journal-title":"J Headache Pain"},{"key":"1429_CR11","first-page":"2014","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine. Headache: The Journal of Head and Face. Pain 60:2014\u20132025","journal-title":"Pain"},{"key":"1429_CR12","unstructured":"Biohaven Pharmaceuticals (2021) NURTEC ODT (rimegepant) [package insert]"},{"key":"1429_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12955-017-0799-1","volume":"15","author":"A Hareendran","year":"2017","unstructured":"Hareendran A, Mannix S, Skalicky A, Bayliss M, Blumenfeld A, Buse DC, Desai PR, Ortmeier BG, Sapra S (2017) Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). Health Qual Life Outcomes 15:224","journal-title":"Health Qual Life Outcomes"},{"key":"1429_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40122-019-0133-1","volume":"8","author":"MJ Doane","year":"2019","unstructured":"Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J (2019) Associations Between Headache-Free Days and Patient-Reported Outcomes Among Migraine Patients: A Cross-Sectional Analysis of Survey Data in Europe. Pain Therapy 8:203\u2013216","journal-title":"Pain Therapy"},{"key":"1429_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20:41","journal-title":"J Headache Pain"},{"key":"1429_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12955-016-0542-3","volume":"14","author":"S Mannix","year":"2016","unstructured":"Mannix S, Skalicky A, Buse DC, Desai P, Sapra S, Ortmeier B, Widnell K, Hareendran A (2016) Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches. Health Qual Life Outcomes 14:143","journal-title":"Health Qual Life Outcomes"},{"key":"1429_CR17","first-page":"105","volume":"51","author":"DS Ng-Mak","year":"2011","unstructured":"Ng-Mak DS, Fitzgerald KA, Norquist JM, Banderas BF, Nelsen LM, Evans CJ, Healy CG, Ho TW, Bigal M (2011) Key Concepts of Migraine Postdrome: A Qualitative Study to Develop a Post-Migraine Questionnaire. Headache: The Journal of Head and Face. Pain 51:105\u2013117","journal-title":"Pain"},{"key":"1429_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/head.13701","volume":"60","author":"CR Houts","year":"2020","unstructured":"Houts CR, Wirth RJ, McGinley JS, Gwaltney C, Kassel E, Snapinn S, Cady R (2020) Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review. Headache 60:28\u201339","journal-title":"Headache"},{"key":"1429_CR19","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1111\/head.13915","volume":"60","author":"RM Speck","year":"2020","unstructured":"Speck RM, Collins EM, Lombard L, Ayer DW (2020) A Qualitative Study to Assess the Content Validity of the 24-Hour Migraine Quality of Life Questionnaire in Patients with Migraine. Headache 60:1982\u20131994","journal-title":"Headache"},{"key":"1429_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017851","volume":"7","author":"D Palacios-Ce\u00f1a","year":"2017","unstructured":"Palacios-Ce\u00f1a D, Neira-Mart\u00edn B, Silva-Hern\u00e1ndez L, Mayo-Canalejo D, Florencio LL, Fern\u00e1ndez-de-Las-Pe\u00f1as C, Garc\u00eda-Moreno H, Garc\u00eda-Azor\u00edn D, Cuadrado ML (2017) Living with chronic migraine: a qualitative study on female patients\u2019 perspectives from a specialised headache clinic in Spain. BMJ Open 7:e017851","journal-title":"BMJ Open"},{"key":"1429_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/head.13569","volume":"59","author":"AK Kawata","year":"2019","unstructured":"Kawata AK, Hareendran A, Shaffer S, Mannix S, Thach A, Desai P, Mikol D, Ortmeier B, Bayliss M, Buse DC (2019) Evaluating the Psychometric Properties of the Migraine Functional Impact Questionnaire (MFIQ). Headache 59:1253\u20131269","journal-title":"Headache"},{"key":"1429_CR22","doi-asserted-by":"crossref","unstructured":"Gandhi P, Lipton RB, Knoble N, Bushnell DM, Niu X, Viswanathan HN (2020) Psychometric Evaluation of the Functional Impact of Migraine Questionnaire Within the COMPEL Trial (144). Neurology 94","DOI":"10.1212\/WNL.94.15_supplement.144"},{"key":"1429_CR23","first-page":"1","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, La\u00ednez JM, Lant\u00e9ri-Minet M, Rastenyte D, Ruiz de la Torre E, Andr\u00e9e C, Steiner TJ (2016) Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain 17:1\u201310","journal-title":"J Headache Pain"},{"key":"1429_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01264-0","volume":"22","author":"SF Kothari","year":"2021","unstructured":"Kothari SF, Jensen RH, Steiner TJ (2021) The relationship between headache-attributed disability and lost productivity: 1. A review of the literature. J Headache Pain 22:1\u20138","journal-title":"J Headache Pain"},{"key":"1429_CR25","doi-asserted-by":"crossref","unstructured":"Sandoe C, Lipton R, Buse D, Ford J, Hand A, Jedynak J, Port M, Detke H (2021) Interictal Burden of Migraine: Correlations with Other Measures of Migraine Burden and Effects of Galcanezumab Migraine-Preventive Treatment (1914). Neurology 96","DOI":"10.1212\/WNL.96.15_supplement.1914"},{"key":"1429_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039","journal-title":"Headache"},{"key":"1429_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3:77\u2013101","journal-title":"Qual Res Psychol"},{"key":"1429_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200826050-00002","volume":"26","author":"NK Leidy","year":"2008","unstructured":"Leidy NK, Vernon M (2008) Perspectives on Patient-Reported Outcomes. PharmacoEconomics 26:363\u2013370","journal-title":"PharmacoEconomics"},{"key":"1429_CR29","unstructured":"VERBI Software (2019) MAXQDA 2020 [computer software]. VERBI Software, Berlin. Available from maxqda.com"},{"key":"1429_CR30","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1080\/03007995.2021.1976738","volume":"37","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Curto M (2021) Unmet needs for migraine. Curr Med Res Opin 37:1957\u20131959","journal-title":"Curr Med Res Opin"},{"key":"1429_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MFT, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422\u2013435","journal-title":"Mayo Clin Proc"},{"key":"1429_CR32","doi-asserted-by":"publisher","unstructured":"Archibald MM, Ambagtsheer RC, Casey MG, Lawless M (2019) Using Zoom Videoconferencing for Qualitative Data Collection: Perceptions and Experiences of Researchers and Participants. Int J Qual Methods. https:\/\/doi.org\/10.1177\/1609406919874596","DOI":"10.1177\/1609406919874596"},{"key":"1429_CR33","doi-asserted-by":"publisher","unstructured":"Carter SM, Shih P, Williams J, Degeling C, Mooney-Somers J (2021) Conducting Qualitative Research Online: Challenges and Solutions. Patient. https:\/\/doi.org\/10.1007\/s40271-021-00528-w","DOI":"10.1007\/s40271-021-00528-w"},{"key":"1429_CR34","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/d41586-020-02867-4","volume":"586","author":"M Eisenstein","year":"2020","unstructured":"Eisenstein M (2020) Closing the gender gap in migraine research. Nature 586:S16\u2013S17","journal-title":"Nature"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01429-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T16:40:12Z","timestamp":1727368812000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01429-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01429-5","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the WIRB-Copernicus Group Independent Review Board (tracking number: 20211304). All participants provided written informed consent prior to the interviews and verbally re-confirmed consent at the start of the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GL, LH, and VC are employed by and own stock\/stock options in Biohaven Pharmaceuticals Inc. SHL, KG, LTH, and EW are employees of Acaster Lloyd Consulting Ltd. AJL is an employee and shareholder of Acaster Lloyd Consulting Ltd. Acaster Lloyd Consulting Ltd were commissioned by Biohaven Pharmaceuticals Inc to conduct the study. TS is an employee of StudyMetrix Research LLC and has received consulting fees from Biohaven Pharmaceuticals Inc in the conduct of this study. LP and KJ are employees of Broadstreet HEOR, which received payment by Biohaven Pharmaceuticals Inc in the conduct of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}